{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:02:11Z","timestamp":1792555331958,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an open-label prospective randomised controlled trial to compare progression of cardiovascular and chronic kidney disease mineral and bone disorder (CKD-MBD) parameters. Patients were randomised to receive cinacalcet alongside standard therapy or standard therapy alone. Thirty-six haemodialysis patients who had &gt;\u200990\u2009days on dialysis, iPTH &gt;\u2009300\u2009pg\/mL, calcium &gt;\u20092.1\u2009mmol\/L and age 18\u201375\u2009years were included. Following randomization, all 36 patients underwent an intensive 12-week period of bone disease management aiming for iPTH 150-300\u2009pg\/mL. The primary outcome was change in vascular calcification using CT agatston score. Secondary outcomes included pulse wave velocity (PWV), left ventricular mass index (LVMI), carotid intima-media thickness (CIMT), augmentation index (Aix) and bone measurements. The above measurements were obtained at baseline and 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no evidence of a group difference in the progression of calcification (median change (IQR) cinacalcet: 488 (0 to1539); standard therapy: 563 (50 to 1214)). In a post hoc analysis combining groups there was a mean (SD) phosphate reduction of 0.3\u2009mmol\/L (0.7) and median (IQR) iPTH reduction of 380\u2009pg\/mL (\u2212\u2009754, 120). Regression of LVMI and CIMT was seen (\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u00a00.03 and\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u00a00.001\n                      <jats:italic>)<\/jats:italic>\n                      and was significantly associated with change of phosphate on multi-factorial analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      With a policy of intense CKD-MBD parameter control, no significant benefit in bone and cardiovascular markers was seen with the addition of cinacalcet to standard therapy over one year. Tight control of hyperphosphataemia and secondary hyperparathyroidism may lead to a reduction in LVMI and CIMT but this needs further investigation\n                      <jats:bold>.<\/jats:bold>\n                      Although the sample size was small, meticulous trial supervision resulted in very few protocol deviations with therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-021-02312-2","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T10:04:10Z","timestamp":1616493850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism"],"prefix":"10.1186","volume":"22","author":[{"given":"Helen","family":"Eddington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-6595","authenticated-orcid":false,"given":"Rajkumar","family":"Chinnadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantina","family":"Chrysochou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibi","family":"Erekosima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Bubtana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hegarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"10","key":"2312_CR1","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504\u201311. https:\/\/doi.org\/10.1681\/ASN.2014070714.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2312_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/aor.12690","volume":"40","author":"S Ulusoy","year":"2016","unstructured":"Ulusoy S, Ozkan G, Guvercin B, Yavuz A. The relation between variability of intact parathyroid hormone, calcium, and cardiac mortality in hemodialysis patients. Artif Organs. 2016;40(11):1078\u201385. https:\/\/doi.org\/10.1111\/aor.12690.","journal-title":"Artif Organs"},{"issue":"3","key":"2312_CR3","doi-asserted-by":"publisher","first-page":"e0173831","DOI":"10.1371\/journal.pone.0173831","volume":"12","author":"R Villa-Bellosta","year":"2017","unstructured":"Villa-Bellosta R, Rodriguez-Osorio L, Mas S, Abadi Y, Rubert M, De La Piedra C, et al. A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients. Jha V, editor. PLoS One. 2017;12(3):e0173831.","journal-title":"PLoS One"},{"key":"2312_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3892\/br.2016.761","volume":"5","author":"GY Wu","year":"2016","unstructured":"Wu GY, Da Xu B, Wu T, Wang XY, Wang TX, Zhang X, et al. Correlation between serum parathyroid hormone levels and coronary artery calcification in patients without renal failure. Biomed Rep. 2016;5:601\u20136. https:\/\/doi.org\/10.3892\/br.2016.761.","journal-title":"Biomed Rep"},{"issue":"2","key":"2312_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14797\/mdcj-13-2-49","volume":"13","author":"SJ Brown","year":"2017","unstructured":"Brown SJ, Ruppe MD, Tabatabai LS. The parathyroid gland and heart Disease. Methodist Debakey Cardiovasc J. 2017;13(2):49\u201354. https:\/\/doi.org\/10.14797\/mdcj-13-2-49.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"2312_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K\/DOQI\u2122 bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760\u201371. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.67139.x.","journal-title":"Kidney Int"},{"issue":"1","key":"2312_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ckj\/sfx125","volume":"11","author":"L Pereira","year":"2018","unstructured":"Pereira L, Meng C, Marques D, Fraz\u00e3o JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J. 2018;11(1):80\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfx125.","journal-title":"Clin Kidney J"},{"issue":"11","key":"2312_CR8","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1097\/HJH.0b013e328357c049","volume":"30","author":"S Jung","year":"2012","unstructured":"Jung S, Querfeld U, M\u00fcller D, Rudolph B, Peters H, Kr\u00e4mer S. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens. 2012;30(11):2182\u201391. https:\/\/doi.org\/10.1097\/HJH.0b013e328357c049.","journal-title":"J Hypertens"},{"issue":"1","key":"2312_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2008.10.043","volume":"205","author":"O Ivanovski","year":"2009","unstructured":"Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE\u2212\/\u2212) mice. Atherosclerosis. 2009;205(1):55\u201362. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.10.043.","journal-title":"Atherosclerosis."},{"issue":"4","key":"2312_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfq725.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2312_CR11","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3109\/0886022X.2014.938544","volume":"36","author":"L Liu","year":"2014","unstructured":"Liu L, Wang Y, Chen H, Zhu X, Zhou L, Yang Y. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Ren Fail. 2014;36(8):1244\u201352. https:\/\/doi.org\/10.3109\/0886022X.2014.938544.","journal-title":"Ren Fail"},{"issue":"3","key":"2312_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","volume":"57","author":"T Kakuta","year":"2011","unstructured":"Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57(3):422\u201331. https:\/\/doi.org\/10.1053\/j.ajkd.2010.10.055.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2312_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","volume":"51","author":"W Qunibi","year":"2008","unstructured":"Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus Sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51(6):952\u201365. https:\/\/doi.org\/10.1053\/j.ajkd.2008.02.298.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2312_CR14","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/ndt\/gfp762","volume":"25","author":"J Floege","year":"2010","unstructured":"Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, et al. Study design and subject baseline characteristics in the ADVANCE study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25(6):1916\u201323. https:\/\/doi.org\/10.1093\/ndt\/gfp762.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 113","key":"2312_CR15","first-page":"S1","volume":"76","author":"Kidney Disease","year":"2009","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1\u2013130.","journal-title":"Kidney Int"},{"issue":"6","key":"2312_CR16","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, De Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfq219.","journal-title":"Nephrol Dial Transplant"},{"key":"2312_CR17","unstructured":"Sakaguchi T, Akizawa T. K\/DOQI clinical practice guidelines for bone metabolism and disease in CKD. Vol. 42. Am J Kidney Dis. 2003:S1\u2013201."},{"issue":"1","key":"2312_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-020-00947-7","volume":"20","author":"H Raad","year":"2020","unstructured":"Raad H, Cornelius V, Chan S, Williamson E, Cro S. An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome. BMC Med Res Methodol. 2020;20(1):1\u201312.","journal-title":"BMC Med Res Methodol"},{"issue":"1\u20133","key":"2312_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejphar.2009.05.013","volume":"616","author":"C Henley","year":"2009","unstructured":"Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X, et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol. 2009;616(1\u20133):306\u201313. https:\/\/doi.org\/10.1016\/j.ejphar.2009.05.013.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"2312_CR20","doi-asserted-by":"publisher","first-page":"F1376","DOI":"10.1152\/ajprenal.90737.2008","volume":"296","author":"I Lopez","year":"2009","unstructured":"Lopez I, Mendoza FJ, Guerrero F, Almaden Y, Henley C, Aguilera-Tejero E, et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J Physiol Ren Physiol. 2009;296(6):F1376\u201385. https:\/\/doi.org\/10.1152\/ajprenal.90737.2008.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"2312_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","volume":"26","author":"M Naves-Daz","year":"2011","unstructured":"Naves-Daz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernndez-Martn JL, Rodrguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES study. Nephrol Dial Transplant. 2011;26(6):1938\u201347. https:\/\/doi.org\/10.1093\/ndt\/gfq304.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2312_CR22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ndt\/gfr447","volume":"27","author":"MR Cust\u00f3dio","year":"2012","unstructured":"Cust\u00f3dio MR, Koike MK, Neves KR, Dos Reis LM, Graciolli FG, Neves CL, et al. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant. 2012;27(4):1437\u201345. https:\/\/doi.org\/10.1093\/ndt\/gfr447.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2312_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10(6):1031\u201340. https:\/\/doi.org\/10.2215\/CJN.07050714.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2312_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1681\/ASN.2005090914","volume":"17","author":"T Odenwald","year":"2006","unstructured":"Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol. 2006;17(3):655\u201362. https:\/\/doi.org\/10.1681\/ASN.2005090914.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2312_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/01.ASN.0000056188.23717.E5","volume":"14","author":"H Ogata","year":"2003","unstructured":"Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol. 2003;14(4):959\u201367. https:\/\/doi.org\/10.1097\/01.ASN.0000056188.23717.E5.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2312_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2010;5(1):110\u20136. https:\/\/doi.org\/10.2215\/CJN.03630509.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2312_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.03270314","volume":"10","author":"SM Sprague","year":"2015","unstructured":"Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2015;10(6):1021\u201330. https:\/\/doi.org\/10.2215\/CJN.03270314.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2312_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12882-015-0030-8","volume":"16","author":"WLS Peter","year":"2015","unstructured":"Peter WLS, Yusuf AA, Do T, Lowe KA, Liu J, Nieman KM, et al. Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study. BMC Nephrol. 2015;16(1):41. https:\/\/doi.org\/10.1186\/s12882-015-0030-8.","journal-title":"BMC Nephrol"},{"issue":"5","key":"2312_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2215\/CJN.04381206","volume":"2","author":"GM Chertow","year":"2007","unstructured":"Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2(5):898\u2013905. https:\/\/doi.org\/10.2215\/CJN.04381206.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"2312_CR30","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GA Block","year":"2012","unstructured":"Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Goodman WG, Herzog CA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"key":"2312_CR31","doi-asserted-by":"publisher","unstructured":"Parfrey PS, Dr\u00fceke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al. Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 2015;10(5):791\u2013799, DOI: https:\/\/doi.org\/10.2215\/CJN.07730814.","DOI":"10.2215\/CJN.07730814"},{"issue":"4","key":"2312_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4103\/0971-4065.59337","volume":"19","author":"N Al-Hilali","year":"2009","unstructured":"Al-Hilali N, Hussain N, Ataia A, Al-Azmi M, Al-Helal B, Johny K. Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. Indian J Nephrol. 2009;19(4):153\u20137. https:\/\/doi.org\/10.4103\/0971-4065.59337.","journal-title":"Indian J Nephrol"},{"issue":"9","key":"2312_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1590\/S0100-879X2005000900016","volume":"38","author":"RB Randon","year":"2005","unstructured":"Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC. The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res. 2005;38(9):1409\u201316. https:\/\/doi.org\/10.1590\/S0100-879X2005000900016.","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"2312_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/fca.11.82","volume":"8","author":"C Karohl","year":"2012","unstructured":"Karohl C, Raggi P. Cinacalcet: will it play a role in reducing cardiovascular events? Futur Cardiol. 2012;8(3):357\u201370. https:\/\/doi.org\/10.2217\/fca.11.82.","journal-title":"Futur Cardiol"},{"issue":"3","key":"2312_CR35","doi-asserted-by":"publisher","first-page":"H1165","DOI":"10.1152\/ajpheart.00821.2005","volume":"290","author":"J Tfelt-Hansen","year":"2006","unstructured":"Tfelt-Hansen J, Hansen JL, Smajilovic S, Terwilliger EF, Haunso S, Sheikh SP. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol. 2006;290(3):H1165\u201371. https:\/\/doi.org\/10.1152\/ajpheart.00821.2005.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2312_CR36","doi-asserted-by":"crossref","unstructured":"Hou Y, Li X, Sun L, Qu Z, Jiang L, Du Y. Phosphorus and mortality risk in end-stage renal disease: A meta-analysis. Vol. 474. Clin Chim Acta Elsevier B.V. 2017:108\u201313.","DOI":"10.1016\/j.cca.2017.09.005"},{"key":"2312_CR37","doi-asserted-by":"crossref","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis. Vol. 305. JAMA. 2011:1119\u201327.","DOI":"10.1001\/jama.2011.308"},{"issue":"1","key":"2312_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000203348","volume":"32","author":"RN Foley","year":"2009","unstructured":"Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adults study. Kidney Blood Press Res. 2009;32(1):37\u201344. https:\/\/doi.org\/10.1159\/000203348.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"2312_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/heartjnl-2011-300570","volume":"98","author":"CD Chue","year":"2012","unstructured":"Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, Ferro CJ. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart. 2012;98(3):219\u201324. https:\/\/doi.org\/10.1136\/heartjnl-2011-300570.","journal-title":"Heart."},{"issue":"9","key":"2312_CR40","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2215\/CJN.03350509","volume":"4","author":"RK Patel","year":"2009","unstructured":"Patel RK, Oliver S, Mark PB, Powell JR, McQuarrie EP, Traynor JP, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol. 2009;4(9):1477\u201383. https:\/\/doi.org\/10.2215\/CJN.03350509.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2312_CR41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.070305","volume":"22","author":"A Card\u00fas","year":"2007","unstructured":"Card\u00fas A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007;22(6):860\u20136. https:\/\/doi.org\/10.1359\/jbmr.070305.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2312_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/ATVBAHA.113.302525","volume":"34","author":"KA Lomashvili","year":"2014","unstructured":"Lomashvili KA, Wang X, O\u2019Neill WC. Role of local versus systemic vitamin D receptors in vascular calcification. Arterioscler Thromb Vasc Biol. 2014;34(1):146\u201351. https:\/\/doi.org\/10.1161\/ATVBAHA.113.302525.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2312_CR43","doi-asserted-by":"crossref","unstructured":"Bover J, Ure\u00f1a P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, et al. Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease. Vol. 34. Semin Nephrol. 2014:626\u201340.","DOI":"10.1016\/j.semnephrol.2014.09.008"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02312-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T10:04:35Z","timestamp":1616493875000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02312-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-118155\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"29 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave written informed consent to participate in the trial. Ethical and MHRA approval was granted by Salford and Trafford Local Research Ethics Committee, approved in November 2005 (ref: 05\/Q1404\/216). The trial conformed to the standards outlined in the 1974 Declaration of Helsinki and was registered retrospectively with the ISRCTN registry (\n                      \n                      ) on 31\/07\/2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PK: Honoraria for lectures and\/or advisory boards: Amgen, Pharmacosmos, Vifor, Fresenius, Napp, MundiPharma, Novonordisk, AstraZeneca, Bayer, Boehringer Ingelheim and research grant support: Astellas, Evotec, Shire, Vifor and BergenBio.HE: Honoraria from Vifor.All other authors \u2013 no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}